Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Dermatology
•
Cutaneous Lymphomas
Would you consider using a JAK inhibitor for CTCL?
Related Questions
After achieving clinical response to bexarotene for cutaneous lymphoma (e.g., MF stage Ib or FMF), do you wean to the lowest dose for sustained remission, and if so, when?
Would you give adjuvant radiation after complete resection of a small primary cutaneous follicular lymphoma of the scalp?
What features on history or physical drive you to order an extended workup in patients with hirsutism or acne?
Do you obtain MRI for cutaneous SCC with microscopic PNI to assess for gross perineural tumor spread?
What therapies have you found most effective for JAK-induced/associated acne (JAKcne)?
Have you encountered idiopathic aseptic facial granuloma in areas other than the face?
Do you always pursue biopsy confirmation before diagnosing IgA vasculitis?
How do you approach the timing of skin tightening interventions in patients who experience significant weight loss to optimize both intermediate and long-term aesthetic outcomes?
How effective is the use of genomic testing methods, such as tape strip tests, for assessing suspicious pigmented lesions in clinical practice?
How often do you recommend ophthalmologic screening exams for patients with sarcoidosis?
